CCNU in the Treatment of Canine Epitheliotropic Lymphoma

Williams, Laurel E.; Rassnick, Kenneth M.; Power, Helen T.; Lana, Susan E.; Morrison-Collister, Kirsten E.; Hansen, Katherine; Johnson, Jeffrey L.

doi:10.1892/0891-6640(2006)20[136:cittoc]2.0.co;2

Cited by 24 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment with lomustine results in the highest response rates (78% to 83%) in dogs, with remission durations of approximately 3 months. 76,78 Information in a report 9 of diffuse conjunctival CETL in a dog indicates that topical treatment with prednisolone acetate followed by additional treatment with synthetic retinoid (isoretinoin) administered orally is sufficient to maintain comfort in animals and prevent worsening of a lesion 6 months after starting isoretinoin treatment. A dog with a focal palpebral conjunctival nonepitheliotropic T-cell lymphoma in another report 11 was free of evidence of recurrence 1 year after surgical resection alone.…”

Section: Discussionmentioning

confidence: 99%

Presumed solitary intraocular or conjunctival lymphoma in dogs and cats: 9 cases (1985–2013)

Wiggans¹,

Skorupski²,

Reilly³

et al. 2014

javma

View full text Add to dashboard Cite

Objective—To determine prevalence, reason for evaluation, treatment, and outcome for dogs and cats with presumed solitary ocular lymphoma (PSOL). Design—Retrospective case series. Animals—7 dogs and 2 cats with PSOL. Procedures—Medical records were reviewed. Progression-free survival time (PFST) and overall survival time (OST) were determined. Results—Animals with intraocular (4 dogs and 1 cat) or conjunctival (3 dogs and 1 cat) lymphoma represented 0.1% and 0.08% of patients with lymphoma evaluated at the hospital during the study period, respectively. Animals with intraocular lymphoma represented 0.19% of all patients with uveitis; animals with conjunctival lymphoma represented 0.16% of all patients with conjunctivitis. Tumors included B-cell (2 intraocular and 1 conjunctival), non–B-cell, non–T-cell (1 intraocular), and T-cell (3 conjunctival) neoplasms; immunophenotype of 2 uveal lymphomas was not determined. Treatments included enucleation (4 intraocular) and chemotherapy (3 intraocular and 2 conjunctival). All dogs with intraocular lymphoma developed neurologic signs. Lymph node metastasis was detected in 2 patients with conjunctival lymphoma. Median PFST and OST were 178 days for all animals with PSOL, dogs with PSOL, and animals with intraocular lymphoma. Median PFST and OST for animals with conjunctival lymphoma were 221 and 549 days, respectively. Conclusions and Clinical Relevance—Results indicated PSOL was uncommon, but should be considered a differential diagnosis for animals with uveitis or conjunctivitis. Performance of MRI and cytologic analysis of CSF and regional lymph node aspirate samples may be beneficial for such patients. Prognosis seemed to be better for animals with conjunctival lymphoma than it was for those with intraocular lymphoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Presumed solitary intraocular or conjunctival lymphoma in dogs and cats: 9 cases (1985–2013)

Wiggans¹,

Skorupski²,

Reilly³

et al. 2014

javma

View full text Add to dashboard Cite

show abstract

“…5,[15][16][17][18] Reported response rates to retinoids, 16 cyclosporine, 18 fatty acids, 5 Lasparaginase, 6 dacarbazine, 15 and pegylated doxorubicin 7 generally are ,50% and are of short duration. A recent publication evaluating 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of ELSA by Williams et al 19 documented an overall response rate of 78%. Consistent with previous reports, the response to CCNU in this study 19 was not durable with a median duration of 106 days.…”

mentioning

confidence: 99%

Response of Canine Cutaneous Epitheliotropic Lymphoma to Lomustine (CCNU): A Retrospective Study of 46 Cases (1999–2004)

Risbon¹,

Lorimier

Skorupski

et al. 2006

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background: Epitheliotropic lymphoma (ELSA) is an uncommon cutaneous canine malignancy of T lymphocytes. A consensus regarding the therapeutic standard of care is lacking, warranting evaluation of chemotherapeutic agents traditionally employed against canine nodal lymphoma in the treatment of ELSA.Hypothesis: The purpose of this retrospective, multi-institutional study was to evaluate the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of ELSA.Animals: Forty-six dogs with adequate follow-up and treatment response information. Methods: All cases were diagnosed histopathologically. Immunohistochemisty (CD3, CD79a) was performed on 42/46 samples.Results: Presenting skin lesions included generalized scales (25/46), plaques or nodules (22/46), mucocutaneous lesions (14/ 46), and corneal involvement (1/46). Lymph node involvement and Sézary syndrome were documented in 7 and 2 dogs, respectively. The median number of CCNU treatments was 4 (range, 1-11), with a median starting dose of 60 mg/m 2 (range, 30-95). Of the 46 dogs, 15 achieved complete remission, 23 achieved partial remission, 5 had stable disease, and 3 had progressive disease, for an overall response rate of 83%. The median number of treatments to achieve a response was 1 (range, 1-6). The overall median duration of response was 94 days (range, 22-282). Sixteen dose reductions were required because of neutropenia (10/46), thrombocytopenia (1/46), anemia (1/46), increased liver enzyme activity (3/46), or unspecified reasons (1/46).Conclusions and Clinical Implications: Given the high response rate and well tolerated protocol, prospective studies are warranted to investigate the utility of CCNU alone or in multi-agent protocols for the treatment of ELSA.

show abstract

“…Segundo alguns autores, alta expressão de Ki-67 é observada nas fases mais avançadas do linfoma cutâneo (DUMMER et al, 1995;GAMBICHLER et al, 2008;EDINGER et al, 2009 Apesar de ainda não haver protocolo estabelecido que controle o linfoma cutâneo a longo prazo, a quimioterapia com a lomustina parece ter maior índice de resposta e maior duração, quando comparada a outros protocolos de tratamento (RISBON et al, 2006;WILLIAMS et al, 2006;LAPRAIS;OLIVRY, 2017).…”

Section: Linfoma Cutâneo Caninounclassified

“…A lomustina é um agente alquilante da classe das nitrosureias que interfere na síntese de DNA e RNA e na reparação de DNA (WEISS; ISSEL, 1982;MOORE et al, 1999;RISBON et al, 2006;WILLIAMS et al, 2006). Em cães, a quimioterapia sistêmica com lomustina é realizada por via oral a cada três semanas com uma dose de 60 a 70 mg/m 2 , sendo que a média de administração é de quatro ciclos de quimioterapia (FONTAINE et al, 2009 …”

Section: Linfoma Cutâneo Caninounclassified

“…Exemplificando, a lomustina é um agente alquilante e o quimioterápico antineoplásico de escolha para o tratamento dos linfomas cutâneos em cães (RISBON et al, 2006;WILLIAMS et al, 2006;LAPRAIS;OLIVRY, 2017), entretanto, os alquilantes não são substrato para o mecanismo de resistência mediado por Pgp, que impediria a atuação do quimioterápico nas células neoplásicas, dessa forma, no caso da lomustina, a resposta ao tratamento seria independente dos transportadores ABC e ainda assim, a resposta ao tratamento não é completa e, caso o seja, a recidiva é muito rápida. Como este fármaco age alquilando o DNA, a resistência à lomustina parece estar relacionada à expressão de moléculas de reparação do material genético como a O 6 -metilguanina-DNA metiltransferase (KAMBAYASHI et al, 2015;TOMASZOWSKI;SCHIRRMACHER;KAINA, 2015).…”

Section: íNdice De Proliferação Celular -Expressão De Ki67unclassified

See 1 more Smart Citation

<b>Estudo da expressão imunoistoquímica de marcadores de resistência a múltiplas drogas em cães com linfoma cutâneo</b>

Alves¹

View full text Add to dashboard Cite

Among mechanisms of resistance are efflux of drugs from intracellular to extracellular through ABC family transporters such as P-glycoprotein, MRP (multple resistance protein) and BCRP (breast cancer resistance protein) and LRP (lung resistance protein), a vault protein responsible for nucleocytoplasmic transport. The aim of this study was to characterize immunophenotypically cutaneous lymphomas, measure cell proliferation using the Ki67 marker, the expression of resistance proteins Pglycoprotein, MRP, BCRP and LRP and to evaluate the relationship of these proteins with the survival of the animals. A retrospective study was performed with 21 cases of dogs with cutaneous lymphoma with histopathological diagnosis.Immunohistochemical was used to immunophenotyping of lymphomas by CD3 and CD20 markers, Ki67 cell proliferation, and P-glycoprotein, MRP, BCRP and LRP expression. Of the 21 animals, 38% had histopathological diagnosis of epitheliotropic lymphoma, 52% were non-epitheliotropic lymphomas, 5% of lymphoma cases had no definition and 5% were classified as round cell neoplasia. The predominant immunophenotype was CD3+CD20-(76%), 15% of the cases were CD3-CD20 + and 9% were CD3 + CD20 +. The median of cells labeled for Ki67 was 31%. Regarding the markers of resistance to multiple drugs, the median of the P-glycoprotein label was 40%, which 65% of LRP while for MRP and BCRP, 19% and 23%, respectively. Non-epitheliotropic cutaneous lymphomas were more frequent than epitheliotropic lymphomas and the predominant immunophenotype was T. The occurrence of CD3-CD20+ and CD3+CD20+ lymphocytes indicates the need for further studies and a wider panel of antibodies for subtyping these lymphomas. P-glycoprotein had higher expression in non-epitheliotropic lymphomas than in epitheliotropic lymphomas and there was no correlation between resistance proteins and survival time of the animals, suggesting that in addition to the biology of neoplasia other mechanisms of resistance to multiple drugs different from those studied may play a relevant role in the low response of cutaneous lymphoma to chemotherapy.

show abstract

CCNU in the Treatment of Canine Epitheliotropic Lymphoma

Cited by 24 publications

References 33 publications

Presumed solitary intraocular or conjunctival lymphoma in dogs and cats: 9 cases (1985–2013)

Presumed solitary intraocular or conjunctival lymphoma in dogs and cats: 9 cases (1985–2013)

Response of Canine Cutaneous Epitheliotropic Lymphoma to Lomustine (CCNU): A Retrospective Study of 46 Cases (1999–2004)

<b>Estudo da expressão imunoistoquímica de marcadores de resistência a múltiplas drogas em cães com linfoma cutâneo</b>

Contact Info

Product

Resources

About